GB9900334D0
(en)
|
1999-01-07 |
1999-02-24 |
Angiogene Pharm Ltd |
Tricylic vascular damaging agents
|
SE9903544D0
(en)
|
1999-10-01 |
1999-10-01 |
Astra Pharma Prod |
Novel compounds
|
GB2359551A
(en)
|
2000-02-23 |
2001-08-29 |
Astrazeneca Uk Ltd |
Pharmaceutically active pyrimidine derivatives
|
AR028948A1
(en)
|
2000-06-20 |
2003-05-28 |
Astrazeneca Ab |
NEW COMPOUNDS
|
US6720323B2
(en)
|
2000-07-07 |
2004-04-13 |
Angiogene Pharmaceuticals Limited |
Colchinol derivatives as angiogenesis inhibitors
|
SE0003828D0
(en)
|
2000-10-20 |
2000-10-20 |
Astrazeneca Ab |
Novel compounds
|
BR0307151A
(en)
|
2002-02-01 |
2004-12-07 |
Astrazeneca Ab |
Compound or a salt thereof, process for preparing it, pharmaceutical composition, use of the compound or salt thereof, method for producing an antiangiogenic and / or vascular permeability reducing effect in a warm-blooded animal such as a human , which requires a treatment of the said type, and processes for the preparation of 5-bromo-7-azaindole, and for the production of 5-methoxy-7-azaindole
|
GB0217431D0
(en)
|
2002-07-27 |
2002-09-04 |
Astrazeneca Ab |
Novel compounds
|
WO2004018435A1
(en)
|
2002-08-24 |
2004-03-04 |
Astrazeneca Ab |
Pyrimidine derivatives as modulators of chemokine receptor activity
|
GB0221828D0
(en)
|
2002-09-20 |
2002-10-30 |
Astrazeneca Ab |
Novel compound
|
MXPA05006918A
(en)
|
2002-12-24 |
2005-08-18 |
Astrazeneca Ab |
Phosphonooxy quinazoline derivatives and their pharmaceutical use.
|
AU2004218412A1
(en)
|
2003-02-28 |
2004-09-16 |
Oxigene, Inc. |
Compositions and methods with enhanced therapeutic activity
|
SE0301010D0
(en)
|
2003-04-07 |
2003-04-07 |
Astrazeneca Ab |
Novel compounds
|
SE0301569D0
(en)
|
2003-05-27 |
2003-05-27 |
Astrazeneca Ab |
Novel compounds
|
JP5046649B2
(en)
|
2003-11-19 |
2012-10-10 |
アレイ バイオファーマ、インコーポレイテッド |
MEK bicyclic inhibitors and methods of use thereof
|
GB0328243D0
(en)
|
2003-12-05 |
2004-01-07 |
Astrazeneca Ab |
Methods
|
MXPA06007692A
(en)
|
2004-01-05 |
2007-01-26 |
Astrazeneca Ab |
Thiophene derivatives as chk 1 inihibitors.
|
SE0401657D0
(en)
|
2004-06-24 |
2004-06-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0415320D0
(en)
|
2004-07-08 |
2004-08-11 |
Astrazeneca Ab |
Novel compounds
|
JP4795352B2
(en)
|
2004-08-28 |
2011-10-19 |
アストラゼネカ・アクチエボラーグ |
Pyrimidinesulfonamide derivatives as chemokine receptor modulators
|
WO2006068953A2
(en)
|
2004-12-21 |
2006-06-29 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
PL1846394T3
(en)
|
2005-02-04 |
2012-04-30 |
Astrazeneca Ab |
Pyrazolylaminopyridine derivatives useful as kinase inhibitors
|
JP5270336B2
(en)
|
2005-05-18 |
2013-08-21 |
アレイ バイオファーマ、インコーポレイテッド |
MEK heterocyclic inhibitors and methods of use thereof
|
CA2615650A1
(en)
|
2005-07-21 |
2007-01-25 |
Astrazeneca Ab |
Novel piperidine derivatives
|
TW200738634A
(en)
|
2005-08-02 |
2007-10-16 |
Astrazeneca Ab |
New salt
|
TW200738658A
(en)
|
2005-08-09 |
2007-10-16 |
Astrazeneca Ab |
Novel compounds
|
WO2007034917A1
(en)
|
2005-09-22 |
2007-03-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
Novel adenine compound
|
JPWO2007034882A1
(en)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
New adenine compounds
|
WO2007034817A1
(en)
|
2005-09-22 |
2007-03-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
Novel adenine compound
|
WO2007034881A1
(en)
|
2005-09-22 |
2007-03-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
Novel adenine compound
|
JPWO2007034916A1
(en)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
New adenine compounds
|
WO2007039736A1
(en)
|
2005-10-06 |
2007-04-12 |
Astrazeneca Ab |
Novel compounds
|
RU2463302C2
(en)
|
2005-10-28 |
2012-10-10 |
Астразенека Аб |
4-(3-aminopyrazole)pyrimidine applicable as tyrosine kinase inhibitors for treating malignant growth
|
KR101086967B1
(en)
|
2005-11-15 |
2011-11-29 |
어레이 바이오파마 인크. |
N4-phenyl-quinazoline-4-amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
|
TW200730512A
(en)
|
2005-12-12 |
2007-08-16 |
Astrazeneca Ab |
Novel compounds
|
CA2633956C
(en)
|
2005-12-13 |
2016-12-06 |
Olivia Raeber |
Binding proteins specific for insulin-like growth factors and uses thereof
|
WO2007068894A2
(en)
|
2005-12-15 |
2007-06-21 |
Astrazeneca Ab |
Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
US7741360B2
(en)
|
2006-05-26 |
2010-06-22 |
Astrazeneca Ab |
Bi-aryl or aryl-heteroaryl substituted indoles
|
CL2007002225A1
(en)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
SPECIFIC UNION AGENT FOR A RECEIVER OF THE GROWTH FACTOR DERIVED FROM PLATES (PDGFR-ALFA); NUCLEIC ACID MOLECULA THAT CODIFIES IT; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CONJUGADO UNDERSTANDING THE AGENT; AND USE OF THE AGENT OF A
|
DE102006037478A1
(en)
|
2006-08-10 |
2008-02-14 |
Merck Patent Gmbh |
2- (Heterocyclylbenzyl) -pyridazinone derivatives
|
EP2057156B1
(en)
|
2006-08-23 |
2017-02-01 |
KuDOS Pharmaceuticals Limited |
2-methylmorpholine pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
|
TW200825084A
(en)
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
CN101610813A
(en)
|
2006-12-19 |
2009-12-23 |
阿斯利康(瑞典)有限公司 |
Quinuclidinol derivatives as muscarinic receptor antagonist
|
CL2008000191A1
(en)
|
2007-01-25 |
2008-08-22 |
Astrazeneca Ab |
COMPOUNDS DERIVED FROM 4-AMINO-CINNOTINA-3-CARBOXAMIDA; CSF-1R QUINASA INHIBITORS; YOUR PREPARATION PROCESS; AND ITS USE TO TREAT CANCER.
|
TW200902018A
(en)
|
2007-03-20 |
2009-01-16 |
Dainippon Sumitomo Pharma Co |
Novel adenine compound
|
JPWO2008114819A1
(en)
|
2007-03-20 |
2010-07-08 |
大日本住友製薬株式会社 |
New adenine compounds
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
DE102007025718A1
(en)
|
2007-06-01 |
2008-12-04 |
Merck Patent Gmbh |
pyridazinone derivatives
|
DE102007025717A1
(en)
|
2007-06-01 |
2008-12-11 |
Merck Patent Gmbh |
Aryl ether pyridazinone derivatives
|
DE102007026341A1
(en)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
UA100983C2
(en)
|
2007-07-05 |
2013-02-25 |
Астразенека Аб |
Biphenyloxypropanoic acid as crth2 modulator and intermediates
|
DE102007032507A1
(en)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
pyridazinone derivatives
|
DE102007038957A1
(en)
|
2007-08-17 |
2009-02-19 |
Merck Patent Gmbh |
6-thioxo-pyridazine derivatives
|
DE102007041115A1
(en)
|
2007-08-30 |
2009-03-05 |
Merck Patent Gmbh |
Thiadiazinonderivate
|
WO2009044200A1
(en)
|
2007-10-04 |
2009-04-09 |
Astrazeneca Ab |
Steroidal [3, 2-c] pyrazole compounds, with glucocorticoid activity
|
WO2009047563A1
(en)
|
2007-10-11 |
2009-04-16 |
Astrazeneca Ab |
Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors
|
EP2604628A3
(en)
|
2007-12-21 |
2013-08-21 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4R) - 173
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
DE102007061963A1
(en)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
pyridazinone derivatives
|
SI2242759T1
(en)
|
2008-02-06 |
2013-01-31 |
Astrazeneca Ab |
Compounds
|
AU2009219376B2
(en)
|
2008-02-28 |
2014-09-25 |
Merck Patent Gmbh |
Protein kinase inhibitors and use thereof
|
DE102008019907A1
(en)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
pyridazinone derivatives
|
CA2721065C
(en)
|
2008-05-27 |
2016-09-27 |
Astrazeneca Ab |
Phenoxypyridinylamide derivatives and their use as pde4 inhibitors
|
DE102008025750A1
(en)
|
2008-05-29 |
2009-12-03 |
Merck Patent Gmbh |
Dihydropyrazolderivate
|
DE102008028905A1
(en)
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3- (3-pyrimidin-2-yl-benzyl) - [1,2,4] triazolo [4,3-b] pyridazine derivatives
|
DE102008029734A1
(en)
|
2008-06-23 |
2009-12-24 |
Merck Patent Gmbh |
Thiazolyl-piperidine derivatives
|
UY31952A
(en)
|
2008-07-02 |
2010-01-29 |
Astrazeneca Ab |
5-METHYLIDENE-1,3-THIAZOLIDINE-2,4-DIONAS REPLACED AS PIM QUINASE INHIBITORS
|
DE102008037790A1
(en)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclic triazole derivatives
|
DE102008038221A1
(en)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-azaindole derivatives
|
WO2010032060A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune Llc |
Antibodies directed to dll4 and uses thereof
|
DE102008052943A1
(en)
|
2008-10-23 |
2010-04-29 |
Merck Patent Gmbh |
azaindole derivatives
|
WO2010067102A1
(en)
|
2008-12-09 |
2010-06-17 |
Astrazeneca Ab |
Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
|
US7863325B2
(en)
|
2008-12-11 |
2011-01-04 |
Axcentua Pharmaceuticals Ab |
Crystalline genistein sodium salt dihydrate
|
CN102292097B
(en)
|
2008-12-11 |
2015-05-27 |
艾克赛特药品有限公司 |
Crystalline forms of genistein
|
US20100152197A1
(en)
|
2008-12-15 |
2010-06-17 |
Astrazeneca Ab |
(4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
|
WO2010077530A1
(en)
|
2008-12-17 |
2010-07-08 |
Merck Patent Gmbh |
C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
|
JP2012512871A
(en)
|
2008-12-18 |
2012-06-07 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Tricyclic azaindole
|
DE102008063667A1
(en)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3- (3-pyrimidin-2-yl-benzyl) - ° [1,2,4] triazolo [4,3-b] pyrimidine derivatives
|
TW201028410A
(en)
|
2008-12-22 |
2010-08-01 |
Astrazeneca Ab |
Chemical compounds 610
|
CA2748158A1
(en)
|
2008-12-23 |
2010-07-01 |
Astrazeneca Ab |
Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
|
DE102008062825A1
(en)
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3- (3-pyrimidin-2-yl-benzyl) - [1,2,4] triazolo [4,3-b] pyridazine derivatives
|
DE102008062826A1
(en)
|
2008-12-23 |
2010-07-01 |
Merck Patent Gmbh |
pyridazinone derivatives
|
DE102009003954A1
(en)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
pyridazinone derivatives
|
DE102009003975A1
(en)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Benzothiazolonderivate
|
DE102009004061A1
(en)
|
2009-01-08 |
2010-07-15 |
Merck Patent Gmbh |
pyridazinone derivatives
|
WO2010089580A1
(en)
|
2009-02-06 |
2010-08-12 |
Astrazeneca Ab |
Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
|
PE20120603A1
(en)
|
2009-02-10 |
2012-06-14 |
Astrazeneca Ab |
TRIAZOLO [4,3-B] PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER
|
GB0905127D0
(en)
|
2009-03-25 |
2009-05-06 |
Pharminox Ltd |
Novel prodrugs
|
UY32520A
(en)
|
2009-04-03 |
2010-10-29 |
Astrazeneca Ab |
COMPOUNDS THAT HAVE AGONIST ACTIVITY OF THE GLUCOCORTICOESTEROID RECEPTOR
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
US20100317593A1
(en)
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
GB0913342D0
(en)
|
2009-07-31 |
2009-09-16 |
Astrazeneca Ab |
Compounds - 801
|
DE102009043260A1
(en)
|
2009-09-28 |
2011-04-28 |
Merck Patent Gmbh |
Pyridinyl-imidazolone derivatives
|
KR20120099639A
(en)
|
2009-10-02 |
2012-09-11 |
아스트라제네카 아베 |
2-pyridone compounds used as inhibitors of neutrophil elastase
|
DE102009049679A1
(en)
|
2009-10-19 |
2011-04-21 |
Merck Patent Gmbh |
Pyrazolopyrimidinderivate
|
WO2011048409A1
(en)
|
2009-10-20 |
2011-04-28 |
Astrazeneca Ab |
Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
|
US8399460B2
(en)
|
2009-10-27 |
2013-03-19 |
Astrazeneca Ab |
Chromenone derivatives
|
BR112012011518B8
(en)
|
2009-11-18 |
2023-01-10 |
Astrazeneca Ab |
COMPOUNDS, PHARMACEUTICAL COMPOSITION, KIT AND USES OF A COMPOUND
|
NZ599405A
(en)
|
2009-11-24 |
2014-09-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
EP2507237A1
(en)
|
2009-12-03 |
2012-10-10 |
Dainippon Sumitomo Pharma Co., Ltd. |
Imidazoquinolines which act via toll - like receptors (tlr)
|
WO2011072791A1
(en)
|
2009-12-14 |
2011-06-23 |
Merck Patent Gmbh |
Sphingosine kinase inhibitors
|
DE102009058280A1
(en)
|
2009-12-14 |
2011-06-16 |
Merck Patent Gmbh |
thiazole
|
JP2013514287A
(en)
|
2009-12-17 |
2013-04-25 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Inhibitors of sphingosine kinase
|
ES2654584T3
(en)
|
2010-01-15 |
2018-02-14 |
Suzhou Neupharma Co., Ltd |
Certain chemical entities, compositions and methods
|
BR112012017884A2
(en)
|
2010-01-19 |
2019-09-24 |
Astrazeneca Ab |
compound, pharmaceutical composition, use of a compound, pyrazine derivative, methods for treatment or prevention, for bone promotion, and for treating bone lesions in cancers
|
WO2011095807A1
(en)
|
2010-02-07 |
2011-08-11 |
Astrazeneca Ab |
Combinations of mek and hh inhibitors
|
WO2011114148A1
(en)
|
2010-03-17 |
2011-09-22 |
Astrazeneca Ab |
4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
|
US20130059916A1
(en)
|
2010-05-26 |
2013-03-07 |
Stephane Rocchi |
Biguanide compounds and its use for treating cancer
|
WO2011154677A1
(en)
|
2010-06-09 |
2011-12-15 |
Astrazeneca Ab |
Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
|
GB201009801D0
(en)
|
2010-06-11 |
2010-07-21 |
Astrazeneca Ab |
Compounds 950
|
SA111320519B1
(en)
|
2010-06-11 |
2014-07-02 |
Astrazeneca Ab |
Pyrimidinyl Compounds for Use as ATR Inhibitors
|
UY33539A
(en)
|
2010-08-02 |
2012-02-29 |
Astrazeneca Ab |
ALK CHEMICAL COMPOUNDS
|
TWI535712B
(en)
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
Chemical compounds
|
DE102010034699A1
(en)
|
2010-08-18 |
2012-02-23 |
Merck Patent Gmbh |
pyrimidine derivatives
|
WO2012027957A1
(en)
|
2010-08-28 |
2012-03-08 |
Suzhou Neupharma Co., Ltd. |
Bufalin derivatives, pharmaceutical compositions and use thereof
|
GB201016442D0
(en)
|
2010-09-30 |
2010-11-17 |
Pharminox Ltd |
Novel acridine derivatives
|
DE102010048800A1
(en)
|
2010-10-20 |
2012-05-10 |
Merck Patent Gmbh |
quinoxaline
|
DE102010049595A1
(en)
|
2010-10-26 |
2012-04-26 |
Merck Patent Gmbh |
quinazoline derivatives
|
WO2012066335A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Phenol compounds als toll -like receptor 7 agonists
|
WO2012066336A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Benzylamine compounds as toll -like receptor 7 agonists
|
WO2012067269A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Aminoalkoxyphenyl compounds and their use in the treatment of disease
|
WO2012067268A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Cyclic amide compounds and their use in the treatment of disease
|
CN103370317B
(en)
|
2010-12-16 |
2015-10-07 |
阿斯利康(瑞典)有限公司 |
Can be used for imidazo [4, the 5-c] quinoline-1-radical derivative for the treatment of
|
DK2651943T3
(en)
|
2010-12-17 |
2017-06-06 |
Sumitomo Dainippon Pharma Co Ltd |
purine derivatives
|
MX2013007067A
(en)
|
2010-12-20 |
2013-11-01 |
Medimmune Ltd |
Anti-il-18 antibodies and their uses.
|
EP2670763B1
(en)
|
2011-02-02 |
2018-08-01 |
Suzhou Neupharma Co., Ltd |
Certain chemical entities, compositions, and methods
|
JP5937112B2
(en)
|
2011-02-17 |
2016-06-22 |
カンサー・セラピューティクス・シーアールシー・プロプライエタリー・リミテッドCancer Therapeutics Crc Pty Limited |
Selective FAK inhibitor
|
WO2012110773A1
(en)
|
2011-02-17 |
2012-08-23 |
Cancer Therapeutics Crc Pty Limited |
Fak inhibitors
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
US8530470B2
(en)
|
2011-04-13 |
2013-09-10 |
Astrazeneca Ab |
Chromenone derivatives
|
WO2012175991A1
(en)
|
2011-06-24 |
2012-12-27 |
Pharminox Limited |
Fused pentacyclic anti - proliferative compounds
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
MX342874B
(en)
|
2011-07-12 |
2016-10-17 |
Astrazeneca Ab |
N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator.
|
SG10201910984XA
(en)
|
2011-07-27 |
2020-01-30 |
Astrazeneca Ab |
2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
|
DE102011111400A1
(en)
|
2011-08-23 |
2013-02-28 |
Merck Patent Gmbh |
Bicyclic heteroaromatic compounds
|
JP6002223B2
(en)
|
2011-08-26 |
2016-10-05 |
ニューファーマ, インコーポレイテッド |
Specific chemical entities, compositions and methods
|
WO2013033250A1
(en)
|
2011-09-01 |
2013-03-07 |
Xiangping Qian |
Certain chemical entities, compositions, and methods
|
EP3332785B1
(en)
|
2011-09-14 |
2020-05-06 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
EP2757885B1
(en)
|
2011-09-21 |
2017-03-15 |
Neupharma, Inc. |
Certain chemical entites, compositions, and methods
|
EP2760458B1
(en)
|
2011-09-29 |
2017-06-14 |
The University of Liverpool |
Prevention and/or treatment of cancer and/or cancer metastasis
|
WO2013049701A1
(en)
|
2011-09-30 |
2013-04-04 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
US9670180B2
(en)
|
2012-01-25 |
2017-06-06 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
BR112014016884A2
(en)
|
2012-01-28 |
2017-06-27 |
Merck Patent Gmbh |
triazolo [4,5-d] pyrimidine derivatives
|
EP2812323B1
(en)
|
2012-02-09 |
2016-04-06 |
Merck Patent GmbH |
Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
|
CA2863985C
(en)
|
2012-02-09 |
2020-08-11 |
Merck Patent Gmbh |
Furo [3,2-b] - and thieno [3,2-b] pyridine derivatives as tbk1 and ikk inhibitors
|
EP2817306B1
(en)
|
2012-02-21 |
2015-09-16 |
Merck Patent GmbH |
Cyclic diaminopyrimidine derivatives as syk inhibitors
|
WO2013124025A1
(en)
|
2012-02-21 |
2013-08-29 |
Merck Patent Gmbh |
Furopyridine derivatives
|
JP6479476B2
(en)
|
2012-02-21 |
2019-03-06 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
8-Substituted 2-amino- [1,2,4] triazolo [1,5-A] pyrazines as Syk Tyrosine Kinase Inhibitors and GCN2 Serine Kinase Inhibitors
|
WO2013131609A1
(en)
|
2012-03-07 |
2013-09-12 |
Merck Patent Gmbh |
Triazolopyrazine derivatives
|
JP6096879B2
(en)
|
2012-03-28 |
2017-03-15 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
Bicyclic pyrazinone derivatives
|
WO2013144532A1
(en)
|
2012-03-30 |
2013-10-03 |
Astrazeneca Ab |
3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
|
EA201401077A1
(en)
|
2012-04-05 |
2015-02-27 |
Ф.Хоффманн-Ля Рош Аг |
BISPECIFIC ANTIBODIES TO HUMAN TWEAK AND HUMAN IL17 AND THEIR APPLICATION
|
WO2013165924A1
(en)
|
2012-04-29 |
2013-11-07 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
PL2844659T3
(en)
|
2012-05-04 |
2016-11-30 |
|
Pyrrolotriazinone derivatives
|
GB201211021D0
(en)
|
2012-06-21 |
2012-08-01 |
Cancer Rec Tech Ltd |
Pharmaceutically active compounds
|
ES2673873T3
(en)
|
2012-07-24 |
2018-06-26 |
Merck Patent Gmbh |
Hydroxystatin derivatives for the treatment of osteoarthritis
|
CN104507942B
(en)
|
2012-08-07 |
2017-03-22 |
默克专利股份公司 |
Pyridopyrimidine derivatives as protein kinase inhibitors
|
SI2882714T1
(en)
|
2012-08-08 |
2020-03-31 |
Merck Patent Gmbh |
(aza-)isoquinolinone derivatives
|
EP2885291A4
(en)
|
2012-08-17 |
2015-11-04 |
Cancer Therapeutics Crc Pty Ltd |
Vegfr3 inhibitors
|
WO2014041349A1
(en)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
|
CN104812389B
(en)
|
2012-09-24 |
2020-07-17 |
润新生物公司 |
Certain chemical entities, compositions, and methods
|
SG11201502120XA
(en)
|
2012-09-26 |
2015-04-29 |
Merck Patent Gmbh |
Quinazolinone derivatives as parp inhibitors
|
JP6348115B2
(en)
|
2012-10-26 |
2018-06-27 |
ザ ユニバーシティー オブ クイーンズランド |
Use of endocytosis inhibitors and antibodies for cancer therapy
|
AU2013337616B2
(en)
|
2012-11-05 |
2019-03-21 |
Gmdx Co Pty Ltd |
Methods for determining the cause of somatic mutagenesis
|
US9725421B2
(en)
|
2012-11-12 |
2017-08-08 |
Neupharma, Inc. |
Substituted quinoxalines as B-raf kinase inhibitors
|
CA2891484A1
(en)
|
2012-11-16 |
2014-05-22 |
Merck Patent Gmbh |
3-aminocyclopentane carboxamide derivatives
|
US9353150B2
(en)
|
2012-12-04 |
2016-05-31 |
Massachusetts Institute Of Technology |
Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
|
RU2656593C2
(en)
|
2013-01-31 |
2018-06-06 |
Неомед Инститьют |
Imidazopyridine compounds useful in treatment of condition associated with p2x3 and/or p2x2/3 activity
|
JP6321685B2
(en)
|
2013-02-25 |
2018-05-09 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
2-Amino-3,4-dihydro-quinazoline derivatives and their use as cathepsin D inhibitors
|
EP2964648B1
(en)
|
2013-03-05 |
2016-11-16 |
Merck Patent GmbH |
9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents
|
CA2905509A1
(en)
|
2013-03-15 |
2014-09-18 |
Memorial Sloan-Kettering Cancer Center |
Hsp90-targeted cardiac imaging and therapy
|
AR095443A1
(en)
|
2013-03-15 |
2015-10-14 |
Fundación Centro Nac De Investig Oncológicas Carlos Iii |
HEREROCICLES CONDENSED WITH ACTION ON ATR
|
CN105142648A
(en)
|
2013-03-15 |
2015-12-09 |
玛格塞蒂克斯公司 |
Magnesium compositions and uses thereof for cancers
|
WO2014161570A1
(en)
|
2013-04-03 |
2014-10-09 |
Roche Glycart Ag |
Antibodies against human il17 and uses thereof
|
WO2014195507A1
(en)
|
2013-06-07 |
2014-12-11 |
Universite Catholique De Louvain |
3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
|
SG11201510369WA
(en)
|
2013-06-25 |
2016-01-28 |
Univ Canberra |
Methods and compositions for modulating cancer stem cells
|
KR102339228B1
(en)
|
2013-08-23 |
2021-12-13 |
뉴파마, 인크. |
Certain chemical entities, compositions, and methods
|
ES2851724T3
(en)
|
2013-09-18 |
2021-09-08 |
Epiaxis Therapeutics Pty Ltd |
Stem cell modulation
|
EP3052660A4
(en)
|
2013-10-01 |
2017-04-26 |
Queensland University Of Technology |
Kits and methods for diagnosis, screening, treatment and disease monitoring
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
JP2017528452A
(en)
|
2014-08-25 |
2017-09-28 |
ユニバーシティ・オブ・キャンベラUniversity of Canberra |
Composition for modulating cancer stem cells and use thereof
|
WO2016077881A1
(en)
|
2014-11-17 |
2016-05-26 |
The University Of Queensland |
Glycoprotein biomarkers for esophageal adenocarcinoma and barrett's esophagus and uses thereof
|
MA41179A
(en)
|
2014-12-19 |
2017-10-24 |
Cancer Research Tech Ltd |
PARG INHIBITOR COMPOUNDS
|
GB201501870D0
(en)
|
2015-02-04 |
2015-03-18 |
Cancer Rec Tech Ltd |
Autotaxin inhibitors
|
GB201502020D0
(en)
|
2015-02-06 |
2015-03-25 |
Cancer Rec Tech Ltd |
Autotaxin inhibitory compounds
|
CN107613769A
(en)
|
2015-02-17 |
2018-01-19 |
润新生物公司 |
Some chemical entities, composition and method
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
USRE49850E1
(en)
|
2015-08-04 |
2024-02-27 |
Aucentra Therapeutics Pty Ltd |
N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
|
CN108603231B
(en)
|
2015-08-26 |
2023-06-30 |
Gmdx私人有限公司 |
Methods for detecting cancer recurrence
|
AU2016377398B2
(en)
|
2015-12-23 |
2022-10-13 |
Repluca Pty Ltd |
Nucleic acid oligomers and uses therefor
|
EP3411061A4
(en)
|
2016-02-01 |
2019-07-10 |
University of Canberra |
Proteinaceous compounds and uses therefor
|
MX2018009867A
(en)
|
2016-02-15 |
2019-05-27 |
Astrazeneca Ab |
Methods comprising fixed intermittent dosing of cediranib.
|
EP4104837A3
(en)
|
2016-04-15 |
2023-04-26 |
Cancer Research Technology Limited |
Heterocyclic compounds as ret kinase inhibitors
|
GB2554333A
(en)
|
2016-04-26 |
2018-04-04 |
Big Dna Ltd |
Combination therapy
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
NZ750182A
(en)
|
2016-07-29 |
2023-03-31 |
Rapt Therapeutics Inc |
Chemokine receptor modulators and uses thereof
|
CA3033370A1
(en)
|
2016-08-15 |
2018-02-22 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
CN110036006B
(en)
|
2016-09-22 |
2022-12-13 |
癌症研究科技有限公司 |
Preparation and use of pyrimidinone derivatives
|
GB201617103D0
(en)
|
2016-10-07 |
2016-11-23 |
Cancer Research Technology Limited |
Compound
|
TWI808066B
(en)
|
2016-12-05 |
2023-07-11 |
美商亞博創新醫藥有限公司 |
Pyrimidine compounds containing acidic groups
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
AU2018214431B2
(en)
|
2017-02-01 |
2021-07-29 |
Aucentra Therapeutics Pty Ltd |
Derivatives of N-cycloalkyl/heterocycloalkyl-4-(imidazo [1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
|
WO2018162625A1
(en)
|
2017-03-09 |
2018-09-13 |
Truly Translational Sweden Ab |
Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
|
GB201704325D0
(en)
|
2017-03-17 |
2017-05-03 |
Argonaut Therapeutics Ltd |
Compounds
|
GB201705971D0
(en)
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
WO2018209239A1
(en)
|
2017-05-11 |
2018-11-15 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
CN108864079B
(en)
|
2017-05-15 |
2021-04-09 |
深圳福沃药业有限公司 |
Triazine compound and pharmaceutically acceptable salt thereof
|
ES2975661T3
(en)
|
2017-05-26 |
2024-07-11 |
Cancer Research Tech Ltd |
BCL6 inhibitors derived from 2-quinolone
|
KR102628675B1
(en)
|
2017-05-26 |
2024-01-25 |
캔써 리서치 테크놀로지 리미티드 |
Inhibitor of BCL6 derived from benzimidazolone
|
US11883405B2
(en)
|
2017-05-31 |
2024-01-30 |
Amplio Pharma Ab |
Pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy
|
AU2017422200B2
(en)
|
2017-07-05 |
2022-11-24 |
E.P.O.S Iasis Research And Development Limited |
Multifunctional conjugates
|
CA3071575A1
(en)
|
2017-08-01 |
2019-02-07 |
Merck Patent Gmbh |
Thiazolopyridine derivatives as adenosine receptor antagonists
|
CA3070903A1
(en)
|
2017-08-18 |
2019-02-21 |
Cancer Research Technology Limited |
Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer
|
JP7287952B2
(en)
|
2017-08-21 |
2023-06-06 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Benzimidazole derivatives as adenosine receptor antagonists
|
CA3073343A1
(en)
|
2017-08-21 |
2019-02-28 |
Merck Patent Gmbh |
Quinoxaline derivatives as adenosine receptor antagonists
|
TWI702205B
(en)
|
2017-10-06 |
2020-08-21 |
俄羅斯聯邦商拜奧卡德聯合股份公司 |
Epidermal growth factor receptor inhibitors
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
NL2019801B1
(en)
|
2017-10-25 |
2019-05-02 |
Univ Leiden |
Delivery vectors
|
US11730736B2
(en)
|
2017-11-06 |
2023-08-22 |
Rapt Therapeutics, Inc. |
Anticancer agents
|
ES2965337T3
(en)
|
2017-11-23 |
2024-04-12 |
Medac Ges Fuer Klinische Spezialpraeparate Mbh |
Pharmaceutical composition for oral administration containing sulfasalazine and/or an organic salt of sulfasalazine, production process and use
|
EP3489222A1
(en)
|
2017-11-23 |
2019-05-29 |
medac Gesellschaft für klinische Spezialpräparate mbH |
Sulfasalazine salts, production processes and uses
|
CA3087805A1
(en)
|
2018-01-15 |
2019-07-18 |
Aucentra Holdings Pty Ltd |
5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
|
GB201801128D0
(en)
|
2018-01-24 |
2018-03-07 |
Univ Oxford Innovation Ltd |
Compounds
|
JP7355758B2
(en)
|
2018-01-26 |
2023-10-03 |
ラプト・セラピューティクス・インコーポレイテッド |
Chemokine receptor modulators and their uses
|
CA3090528A1
(en)
|
2018-02-08 |
2019-08-15 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
WO2019175093A1
(en)
|
2018-03-12 |
2019-09-19 |
Astrazeneca Ab |
Method for treating lung cancer
|
WO2019197842A1
(en)
|
2018-04-13 |
2019-10-17 |
Cancer Research Technology Limited |
Bcl6 inhibitors
|
JP7427655B2
(en)
|
2018-04-27 |
2024-02-05 |
スプルース バイオサイエンシーズ,インク. |
Methods for Treating Testicular Adrenal Residual Tumors and Ovarian Adrenal Residual Tumors
|
GB201809102D0
(en)
|
2018-06-04 |
2018-07-18 |
Univ Oxford Innovation Ltd |
Compounds
|
WO2019236496A1
(en)
|
2018-06-04 |
2019-12-12 |
Apros Therapeutics, Inc. |
Pyrimidine compounds containing acidic groups useful to treat diseases connected to the modulation of tlr7
|
JP2021527051A
(en)
|
2018-06-05 |
2021-10-11 |
ラプト・セラピューティクス・インコーポレイテッド |
Pyrazolo-pyrimidine-amino-cycloalkyl compounds and their therapeutic use
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
CN118255772A
(en)
|
2018-09-18 |
2024-06-28 |
苏州赞荣医药科技有限公司 |
Quinazoline derivatives as antitumor agents
|
US11084829B2
(en)
|
2018-09-24 |
2021-08-10 |
Rapt Therapeutics, Inc. |
Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof
|
EP3870582B1
(en)
|
2018-10-25 |
2023-07-19 |
Merck Patent GmbH |
5-azaindazole derivatives as adenosine receptor antagonists
|
MX2021003508A
(en)
|
2018-10-25 |
2021-05-27 |
Merck Patent Gmbh |
5-azaindazole derivatives as adenosine receptor antagonists.
|
GB201819126D0
(en)
|
2018-11-23 |
2019-01-09 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
US20230272402A1
(en)
|
2018-12-25 |
2023-08-31 |
Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences |
Small rna medicament for prevention and treatment of inflammation-related diseases and combination thereof
|
AR117844A1
(en)
|
2019-01-22 |
2021-09-01 |
Merck Patent Gmbh |
THIAZOLOPYRIDINE DERIVATIVES AS ANTAGONISTS OF THE ADENOSINE RECEPTOR
|
EP3935049A1
(en)
|
2019-03-07 |
2022-01-12 |
Merck Patent GmbH |
Carboxamide-pyrimidine derivatives as shp2 antagonists
|
CN111747950B
(en)
|
2019-03-29 |
2024-01-23 |
深圳福沃药业有限公司 |
Pyrimidine derivatives for the treatment of cancer
|
US20230085408A1
(en)
|
2019-04-05 |
2023-03-16 |
STORM Therapeutics Ltd. |
Mettl3 inhibitory compounds
|
EP3952998A1
(en)
|
2019-04-08 |
2022-02-16 |
Merck Patent GmbH |
Pyrimidinone derivatives as shp2 antagonists
|
GB201905328D0
(en)
|
2019-04-15 |
2019-05-29 |
Azeria Therapeutics Ltd |
Inhibitor compounds
|
WO2020247054A1
(en)
|
2019-06-05 |
2020-12-10 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
GB201908885D0
(en)
|
2019-06-20 |
2019-08-07 |
Storm Therapeutics Ltd |
Therapeutic compounds
|
AU2020335054A1
(en)
|
2019-08-31 |
2022-03-24 |
Etern Biopharma (Shanghai) Co., Ltd. |
Pyrazole derivative for FGFR inhibitor and preparation method therefor
|
US20220389003A1
(en)
|
2019-09-20 |
2022-12-08 |
Ideaya Biosciences, Inc. |
4-substituted indole and indazole sulfonamido derivatives as parg inhibitors
|
GB201913988D0
(en)
|
2019-09-27 |
2019-11-13 |
Celleron Therapeutics Ltd |
Novel treatment
|
GB201914860D0
(en)
|
2019-10-14 |
2019-11-27 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
GB201915829D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915831D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915828D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
MX2022006700A
(en)
|
2019-12-02 |
2022-09-02 |
Storm Therapeutics Ltd |
Polyheterocyclic compounds as mettl3 inhibitors.
|
GB202004960D0
(en)
|
2020-04-03 |
2020-05-20 |
Kinsenus Ltd |
Inhibitor compounds
|
US20230183197A1
(en)
|
2020-06-01 |
2023-06-15 |
Neophore Limited |
Inhibitors of mlh1 and/or pms2 for cancer treatment
|
GB202012482D0
(en)
|
2020-08-11 |
2020-09-23 |
Univ Of Huddersfield |
Novel compounds and therapeutic uses thereof
|
GB202012969D0
(en)
|
2020-08-19 |
2020-09-30 |
Univ Of Oxford |
Inhibitor compounds
|
WO2022074379A1
(en)
|
2020-10-06 |
2022-04-14 |
Storm Therapeutics Limited |
Mettl3 inhibitory compounds
|
US20240101589A1
(en)
|
2020-10-08 |
2024-03-28 |
Strom Therapeutics Limited |
Inhibitors of mettl3
|
WO2022182415A1
(en)
|
2021-02-24 |
2022-09-01 |
Massachusetts Institute Of Technology |
Himastatin derivatives, and processes of preparation thereof, and uses thereof
|
GB202102895D0
(en)
|
2021-03-01 |
2021-04-14 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
WO2022197641A1
(en)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
|
CN117222435A
(en)
|
2021-05-03 |
2023-12-12 |
默克专利有限公司 |
HER 2-targeted Fc antigen binding fragment-drug conjugates
|
BR112023024040A2
(en)
|
2021-05-17 |
2024-02-06 |
Hk Inno N Corp |
COMPOUND, THE OPTICAL ISOMER THEREOF, THE SOLVATE THEREOF, THE HYDRATE THEREOF OR THE PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND THEIR USE, PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUND, FUNCTIONAL HEALTH FOOD COMPOSITION AND COMBINED PREPARATION
|
CA3221411A1
(en)
|
2021-05-25 |
2022-12-01 |
Merck Patent Gmbh |
Egfr targeting fc antigen binding fragment-drug conjugates
|
GB202107907D0
(en)
|
2021-06-02 |
2021-07-14 |
Storm Therapeutics Ltd |
Combination therapies
|
GB202108383D0
(en)
|
2021-06-11 |
2021-07-28 |
Argonaut Therapeutics Ltd |
Compounds useful in the treatment or prevention of a prmt5-mediated disorder
|
GB202110373D0
(en)
|
2021-07-19 |
2021-09-01 |
Neophore Ltd |
Inhibitor compounds
|
CA3225500A1
(en)
|
2021-10-04 |
2023-04-13 |
Ulrich Luecking |
Parg inhibitory compounds
|
WO2023057394A1
(en)
|
2021-10-04 |
2023-04-13 |
Forx Therapeutics Ag |
N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
|
GB202117224D0
(en)
|
2021-11-29 |
2022-01-12 |
Neophore Ltd |
Inhibitor compounds
|
GB202117225D0
(en)
|
2021-11-29 |
2022-01-12 |
Neophore Ltd |
Protac compounds
|
WO2023131690A1
(en)
|
2022-01-10 |
2023-07-13 |
Merck Patent Gmbh |
Substituted heterocycles as hset inhibitors
|
GB202202006D0
(en)
|
2022-02-15 |
2022-03-30 |
Chancellor Masters And Scholars Of The Univ Of Oxford |
Anti-cancer treatment
|
GB202202199D0
(en)
|
2022-02-18 |
2022-04-06 |
Cancer Research Tech Ltd |
Compounds
|
WO2023175185A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
WO2023175184A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
GB202204935D0
(en)
|
2022-04-04 |
2022-05-18 |
Cambridge Entpr Ltd |
Nanoparticles
|
WO2023196432A1
(en)
|
2022-04-06 |
2023-10-12 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
WO2023218201A1
(en)
|
2022-05-11 |
2023-11-16 |
Cancer Research Technology Limited |
Ikk inhibitors
|
GB202209404D0
(en)
|
2022-06-27 |
2022-08-10 |
Univ Of Sussex |
Compounds
|
WO2024030825A1
(en)
|
2022-08-01 |
2024-02-08 |
Neupharma, Inc |
Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
|
GB202213163D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213164D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213166D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213167D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213162D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Prodrugs
|
WO2024074497A1
(en)
|
2022-10-03 |
2024-04-11 |
Forx Therapeutics Ag |
Parg inhibitory compound
|
WO2024094963A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
|
WO2024094962A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer
|
WO2024099898A1
(en)
|
2022-11-07 |
2024-05-16 |
Merck Patent Gmbh |
Substituted bi-and tricyclic hset inhibitors
|
GB202218672D0
(en)
|
2022-12-12 |
2023-01-25 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
GB202300881D0
(en)
|
2023-01-20 |
2023-03-08 |
Neophore Ltd |
Inhibitor compounds
|